Neuberger Berman Group
PTGX icon

Neuberger Berman Group’s Protagonist Therapeutics PTGX Stock Holding History

Neuberger Berman Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.1M Buy
302,427
+160,986
+114% +$16.8M 0.02% 573
2026
Q1 		$14.9M Buy
141,441
+42,968
+44% +$3.8M 0.01% 729
2025
Q4 		$8.6M Sell
98,473
-24,904
-20% -$2.04M 0.01% 839
2025
Q3 		$8.2M Buy
123,377
+29,795
+32% +$1.69M 0.01% 851
2025
Q2 		$5.17M Buy
+93,582
New +$4.49M ﹤0.01% 959

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Neuberger Berman Group's PTGX Position: Q2 2026 in Review

Neuberger Berman Group increased its Protagonist Therapeutics (PTGX) stake by 114% in Q2 2026, buying an estimated $16.8M and bringing the position to 302,427 shares worth $37.1M. The position accounts for 0.02% of the portfolio, ranked #573.

Neuberger Berman Group first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Neuberger Berman Group held 302,427 shares of Protagonist Therapeutics worth $37.1M as of Q2 2026.
  • Neuberger Berman Group bought 160,986 Protagonist Therapeutics shares in Q2 2026, an estimated $16.8M.
  • Protagonist Therapeutics made up 0.02% of Neuberger Berman Group's portfolio in Q2 2026, its #573 holding.
  • Neuberger Berman Group first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.